SC
CHRS icon

Savant Capital’s Coherus Oncology CHRS Stock Holding History

Savant Capital’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-93,984
Closed -$130K – 1150
2024
Q4 		$130K Buy
+93,984
New +$105K ﹤0.01% 1361
2024
Q3 		– Sell
-32,883
Closed -$56.9K – 1402
2024
Q2 		$56.9K Buy
+32,883
New +$66.2K ﹤0.01% 1235

Other funds holding CHRS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Savant Capital's CHRS Position: Q1 2025 in Review

Savant Capital sold out of Coherus Oncology (CHRS) in Q1 2025, closing a stake of 93,984 shares — an estimated $130K sold.

Savant Capital first reported a position in CHRS in Q2 2024 and held it in 2 quarters. The position peaked at $130K in Q4 2024. 117 funds tracked by Wall St. Rank hold CHRS as of Q1 2025.

  • Savant Capital reported no remaining Coherus Oncology position as of Q1 2025 after selling out during the quarter.
  • Savant Capital sold 93,984 Coherus Oncology shares in Q1 2025, an estimated $130K.
  • Savant Capital first reported a position in Coherus Oncology in Q2 2024 and held it in 2 quarters.
  • Savant Capital's Coherus Oncology position peaked at $130K in Q4 2024.
  • 117 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2025.

Based on Savant Capital's 13F filing for Q1 2025, filed 8 May 2025.